Blog

Popper and Co. to Present New Framework for Economic Evaluation of Diagnostics in the Era of Precision Medicine at Next Generation Dx Summit

Popper and Co., a strategy consulting and transaction advisory firm serving the needs of the medical technology and life sciences industries, announced today that Co-Founder and President Caroline Popper, M.D., will speak at the 10th Annual Next Generation Dx Summit on August 22 at 5 pm ET at the Grand Hyatt Washington in Washington, DC.

In the era of precision medicine, it’s more important than ever to understand how to apply diagnostic tools efficiently to deliver the right therapy to the right patient at the right time – and to do so cost effectively. During the conference session, entitled “Health Economics of Diagnostics and Immunotherapy,” Dr. Popper will highlight a case study examining the economic value of testing a patient’s microbiome before commencing immunotherapy. The case study stems from a partnership between Popper and Co. and Monument Analytics that illustrates the value of “Precision Econostics,” the firms’ new joint offering for biopharmaceutical companies designed to enhance drug adoption through the use of advanced diagnostics.

Precision Econostics utilizes health economic analytic methods and advanced diagnostics expertise to design optimal companion diagnostics strategies for biopharmaceutical clients. To learn more about this unique service, visit www.preconostix.com.

Click here to read the entire press release.